🔥 #RESHAPE_HF2 High time to discover the grey part between the white & black side of the 🌖 #MitraClip in #FMR & #HFrEF 👉 Intermediate characteristics between #COAPT & #MITRA_FR 👉 ⬆️ #ARNI & #STLT2i use 🍀soon at #ESCCongress EJHF Editor-in-Chief European Society of Cardiology Journals Amr Abdin Henry Han

Contemporary challenges and approaches for the management of women Dx with #PPCM : A statement from the #HFA and the #ACNAP of European Society of Cardiology Amina Mark Petrie ACNAPPresident Maggie Simpson onlinelibrary.wiley.com/doi/full/10.10… Henry Han Amr Abdin Giuseppe Galati #EJHF

Interesting to see how long-term mortality changes in non-ischaemic HFrEF with the methods used for evaluation of adiposity. Nevertheless, no matter how you look at it, there seems to be a clear association between greater adiposity and higher mortality. doi.org/10.1002/ejhf.3…

This interesting network meta-analysis investigated prognostic implications of genotype findings in non-ischaemic #DCM See the full findings here 👇🏻onlinelibrary.wiley.com/doi/10.1002/ej… #EJHF European Society of Cardiology Journals Henry Han Amr Abdin Giuseppe Galati European Society of Cardiology

Diving into the intricacies of ICI & VEGFI combination trials 🧪: Disparity in CV exclusion criteria, baseline traits & #MACE reporting present challenges for understanding incidence & severity of events w/ these combinations. Learn more: bit.ly/3UJ7muz #JACCCardioOnc

🗞️ Implementation of #GDMT for #HeartFailure : Progress achieved, work ahead ! #EJHF 🔝 European Society of Cardiology Journals Giuseppe Galati Amr Abdin Henry Han HFAPresident Pardeep S Jhund bit.ly/3SZSXZB

#ESCcongress 2024 Mark Petrie : Refreshing our memory over the Secret trial: A small trial exploring diet and exercise on exercise tolersnce in HfPEF. Modest effects, as we can see...But effect of Semaglutide STEP-HFPEF on exercise tolerance and KCCQ? It was crystal clear!

Continuing: Mark Petrie : interaction between NT-ProBNP and improvement in KCCQ-CSS by semaglutide. Also a similar study w/tirzepatide yet to be published (Summit) provided positive results on both primary outcomes (See picture attached). #ESCCongress 2024

#ESCCongress and The Lancet Long live #Semaglutide Now in HFpEF too- 31% reduction in CVD death or HF thelancet.com/journals/lance… NICE time to update your guidance! Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Mamas A. Mamas Dr Anastasia Mihailidou FAHA FCSANZ FESC Hany Ragy Henry Han Vasiliki Tsampasian eva Maria Papathanasiou

Delighted to present these data today from the DETERMINE trials at the #ESCCongress The first evidence of a beneficial effect of a HF therapy on accelerometer-based measures of physical activity. A promising new outcome measure for HF trials.

ESC guidelines for PCI in severe LV impairment changed from 2a LoE C (should be done in most patients, based on consensus) to 2b LoE B (may be done in selected patients, based on randomised data).#ESCCongress 🙏🏽REVIVED investigators for providing the supporting evidence

Fantastic today that 2 landmark RCTs our centre University Hospitals Dorset NHS Foundation Trust recruited patients for impacted ESC guidelines to direct future care: OCTOBER Trial pushing IC imaging toward 1A REVIVED shifting PCI in ICM down to 2bB Great CI leadership Niels R. Holm & Divaka Perera #researchwin🏆

#FINEARTS_HF #Finerenone is a new pillar for #HFmrEF & #HFpEF The need of new #2025 #HFguidelines is now urgent ‼️ Michele Senni Danielle Belardo, MD ANMCO SIC Società Italiana di Cardiologia SABOURETCardiologist Erik Rafflenbeul Arrigo F.G. Cicero Federica Fogacci Maciej Banach European Society of Cardiology Mark Petrie Zurich Heart House (ZHH)

How do we reconcile STICH and REVIVED? Would CABG offer survival benefit with contemporary medical therapy? ➡️ Answers at late breaking science session #ESCCongress2024 this morning! Results from the first pooled individual patient level analyses from these two RCTs

Fascinating talks using pooled data from REVIVED (R) + STICH (S) ➡️ R patients had higher baseline surgical risk ➡️ No difference in tx effect in either trial by surgical risk ➡️ S-OMT arm had worse outcomes than R-OMT ➡️ R-OMT arm had better outcomes than S-CABG! #ESCCongress

🔥Hot of the press as simultaneous publication in #EHJ‼️ ➡️Bromocriptine and outcomes in peripartum cardiomyopathy: the EORP #PPCM registry ⁦@Karen.Sliwa1⁩ ⁦Mark Petrie⁩ ⁦Giuseppe Galati⁩ ⁦⁦Hannover Medical School⁩ David Duncker⁩ ⁦ academic.oup.com/eurheartj/adva…

Matt Daniels MD PhD Matt Ryan Guillaume Marquis-Gravel Divaka Perera Mark Petrie REVIVED Eric J Velazquez Aaysha Cader European Society of Cardiology Dr Peter O'Kane EHJ Editor-in-Chief Similar BB and ACEi usage in both Plus small amount of entresto use in R, but minimal SGLT2 Over 50% had a device in REVIVED by trial end ahajournals.org/doi/10.1161/CI…

As I head out of London I thought it was a good time to reflect on the past few days. It’s been busy, but it’s important to remain aware that’s it’s an amazing privilege to be able to exchange ideas with so many friends and colleagues, and participate in our global EP community

New in #JACCHF: REVIVED-BCIS2 showed PCI in addition to #GDMT in #ICM did not improve health status beyond 6 months compared with #GDMT alone. PCI should not be recommended for all ICM. jacc.org/doi/10.1016/j.… Editorial: jacc.org/doi/10.1016/j.…

2 year results of REVIVED-BCIS2 Trial: PCI did not improve the hierarchical composite of death, HHF, and health status at 2 years. PCI improved KCCQ-OSS at 6 months, but not sustained to 1- or 2-year follow-up. jacc.org/doi/10.1016/j.… JACC Journals #JACCHF